Market Turmoil? Look At Healthcare Dividend Stocks With 3%+ Yields

The S&P 500’s 9% decline in 2025, triggered by President Trump’s tariffs and heightened trade tensions with China, has created a challenging investment landscape. Despite this downturn, select healthcare stocks show resilience by offering attractive dividend yields exceeding 3%, consistent dividend growth histories, and relative insulation from direct trade conflict impacts. For investors seeking reduced volatility during these uncertain times, these three healthcare sector options merit serious consideration. However, if you seek upside with less volatility than a single stock, consider the High-Quality portfolio, which has outperformed the S&P 500 and achieved returns greater than 91% since inception.

Image by Thomas Breher from Pixabay

1. Bristol Myers Squibb (BMY)

Key Investment Attributes:

• Robust 3.9% dividend yield with 3.4% average annual dividend growth over three years
• Impressive 7% revenue growth in the last twelve months
• Strong profitability with 12% operating margin and over 30% operating cash flow margins
• Already experienced a 10% correction this year, potentially limiting further downside

Strategic Advantages:

• Pharmaceutical products currently exempt from tariff implementations
• Successfully offsetting declining legacy product sales through strategic growth in newer portfolio offerings
• FDA approval of Cobenfy strengthens product lineup, while a promising drug pipeline provides future growth catalysts
• Diversified revenue streams across multiple therapeutic areas reduce dependency on any single market

2. Merck (MRK)

Key Investment Attributes:

• Attractive 3.5% dividend yield complemented by substantial 5.7% annual dividend growth rate
• Solid 7% revenue growth in the last twelve months
• Exceptional profitability demonstrated by approximately 30% cash flow and operating margins
• Stock has already undergone a significant 20% correction this year, partly due to slowing Gardasil vaccine sales in China

Strategic Advantages:

• Protection from tariff impacts due to pharmaceutical exemption status
• Keytruda continues its market dominance with expanding approvals, generating $30 billion in annual sales with three years of market exclusivity remaining
• Robust pipeline featuring multiple promising blockbuster candidates including MK0616, Bomedemstat, and Patritumab Deruxtecan
• Strong research and development capabilities with consistent innovation track record across multiple therapeutic areas

3. Medtronic (MDT)

Key Investment Attributes:

• Reliable 3.1% dividend yield with steady 3% annual dividend growth
• Moderate 2% revenue growth in the last twelve months, offset by respectable 18% operating margin and 22% operating cash flow margin
• Positive stock performance this year despite broader market weakness

Strategic Advantages:

• Minimal China exposure, with imports accounting for less than 1% of revenue while China sales represent only 7% of total revenue
• Surgical innovations and diabetes portfolio now experiencing accelerated double-digit growth
• Market leadership position in multiple medical device categories creates sustained competitive advantages
• Recurring revenue model from consumable products provides stability during economic uncertainty

Takeaway

In the current market environment characterized by heightened volatility and trade tensions, these three healthcare dividend stocks offer a balanced income generation with defensive positioning in response to the 2025 market downturn. These healthcare dividend leaders warrant strong consideration as core holdings for weathering the current economic storm while maintaining exposure to long-term healthcare sector growth.

You can also look at Trefis RV strategy that has outperformed its all-cap stocks benchmark (combination of all 3, the S&P 500, S&P mid-cap, and Russell 2000), to produce strong returns for investors. Separately, if you want upside with a smoother ride than an individual stocks, consider the High Quality portfolio, which has outperformed the S&P, and clocked >91% returns since inception.